Education
About Us
Working with TipRanks
Follow Us
ARKG - ETF AI Analysis
Top Page
ARK Genomic Revolution ETF (ARKG)
Rating:55Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has shown solid gains so far this year and in recent months, indicating positive momentum in its strategy.
Top Holdings Showing Strength
Several of the largest positions, including key genomics companies, have delivered strong year-to-date performance, helping drive the fund’s returns.
Focused Exposure to Genomics Innovation
The fund is heavily focused on health care and genomics companies, giving investors targeted access to a fast-evolving area of medical technology.
Negative Factors
High Expense Ratio
The ETF charges relatively high fees compared with many broad market funds, which can eat into long-term returns.
Sector Concentration Risk
Almost all assets are in the health care sector, so the fund is highly sensitive to downturns or regulatory changes affecting this industry.
Geographic Concentration in the U.S.
With nearly all holdings tied to U.S. companies, the ETF offers little geographic diversification and is heavily exposed to U.S.-specific risks.
ARKG vs. SPDR S&P 500 ETF (SPY)
AUM1.26B
RegionGlobal
Expense Ratio0.75%
Beta1.66
IssuerARK
Inception DateOct 31, 2014
Dividend YieldN/A
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume2,892,769
30 Day Avg. Volume2,812,088
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
44.12Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering34
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ARKG Summary
ARK Genomic Revolution ETF (ARKG) is a thematic fund that focuses on companies working with DNA, gene editing, and advanced medical testing, mainly in the U.S. health care sector. It does not track a traditional index but is actively managed to follow the genomics theme. The fund holds innovative names like Illumina and Crispr Therapeutics, which are involved in DNA sequencing and gene-editing technology. Someone might invest in ARKG for long-term growth potential in cutting-edge medical science. A key risk is that these early-stage biotech companies can be very volatile and their stock prices can swing sharply.
How much will it cost me?The ARK Genomic Revolution ETF (ARKG) has an expense ratio of 0.75%, which means you’ll pay $7.50 per year for every $1,000 invested. This is higher than average because the fund is actively managed, allowing it to focus on innovative companies in the fast-evolving genomics sector.
What would affect this ETF?The ARK Genomic Revolution ETF (ARKG) could benefit from continued advancements in genomic technologies like CRISPR and bioinformatics, as well as increased global investment in healthcare innovation. However, it may face challenges from regulatory hurdles in biotechnology, potential economic downturns affecting funding for research, and competition within the healthcare sector. Its global exposure and focus on cutting-edge companies provide growth potential, but also come with risks tied to market volatility and the success of its top holdings.
ARKG Top 10 Holdings
ARKG is a pure play on cutting-edge health care, with nearly all its firepower in genomic and biotech names and a global tilt, though many flagships are U.S.-listed. 10x Genomics, Guardant Health, Illumina, and Twist Bioscience are doing the heavy lifting lately, with rising momentum that’s helping the fund regain its footing. On the flip side, Tempus AI, Crispr Therapeutics, and Recursion have been lagging, acting like a headwind. Overall, the ETF is concentrated in a few high‑beta innovators, so performance swings can be sharp.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Tempus AI, Inc. Class A | 9.16% | $116.40M | $9.99B | -21.84% | 52 Neutral | |
| Crispr Therapeutics AG | 9.03% | $114.73M | $5.14B | 8.35% | 40 Underperform | |
| Twist Bioscience | 8.85% | $112.52M | $3.37B | 16.44% | 43 Neutral | |
| Personalis | 5.95% | $75.63M | $799.24M | 64.09% | 49 Neutral | |
| 10x Genomics | 5.06% | $64.31M | $2.50B | 66.00% | 60 Neutral | |
| Beam Therapeutics | 5.03% | $63.94M | $2.80B | -15.87% | 58 Neutral | |
| Guardant Health | 4.72% | $60.00M | $13.90B | 124.43% | 61 Neutral | |
| Natera | 4.10% | $52.15M | $29.81B | 28.64% | 73 Outperform | |
| Illumina | 3.82% | $48.61M | $18.36B | 23.46% | 71 Outperform | |
| Recursion Pharmaceuticals | 3.69% | $46.84M | $1.84B | -64.06% | 52 Neutral |
ARKG Technical Analysis
Positive
―
Price Trends
30.41
Negative
30.14
Negative
27.13
Positive
Market Momentum
-0.53
Positive
49.67
Neutral
76.98
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For ARKG, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 30.15, equal to the 50-day MA of 30.41, and equal to the 200-day MA of 27.13, indicating a neutral trend. The MACD of -0.53 indicates Positive momentum. The RSI at 49.67 is Neutral, neither overbought nor oversold. The STOCH value of 76.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ARKG.
ARKG Peer Comparison
Comparison Results
Performance Comparison
ARKG
ARK Genomic Revolution ETF
29.87
2.93
10.88%
BAI
iShares A.I. Innovation and Tech Active ETF
―
―
―
ARKK
Ark Innovation Etf
―
―
―
ARKQ
ARK Autonomous Technology & Robotics ETF
―
―
―
FWD
AB Disruptors ETF
―
―
―
ARKW
ARK Next Generation Internet ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents